Simple cycle review framework Review point Baseline What to check Research goal, measurements, route, and materials Reason Creates a clear starting point Review point Week 4 What to check Tolerance, handling, and protocol consistency Reason Finds early problems Review point Week 8 What to check Trend compared with baseline Reason Tests whether the plan is producing useful data Review point Week 12 What to check Full review of benefits, limits, and uncertainty Reason Prevents an automatic extension Review point Week 16 or later What to check Reason for continuing and remaining evidence gaps Reason Longer subcutaneous timelines are not clinically established When a Longer Cycle Is Not Supported There is no published evidence showing that extending AOD-9604 beyond 12 or 16 weeks improves the outcome of a community subcutaneous plan
For example, 1,000 mcg is 1 mL if the concentration is 1,000 mcg/mL
A lack of it can be a cause of anaemia (pernicious anaemia) which leads to a reduced about of oxygen being carried around the body in the blood
While the thigh is a common area for intramuscular injections, you can also inject subcutaneously if you have enough fat there
AOD-9604's value is more mechanistic (isolated lipolysis study) than outcome-driven